Thomas Grellety
Overview
Explore the profile of Thomas Grellety including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
516
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peyraud F, Guegan J, Rey C, Lara O, Odin O, Del Castillo M, et al.
Cell Rep Med
. 2025 Feb;
6(2):101934.
PMID: 39909044
Effectiveness of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) has been linked to the presence of mature tertiary lymphoid structures (mTLSs) within the tumor microenvironment (TME). However,...
2.
Audureau E, Soubeyran P, Martinez-Tapia C, Bellera C, Bastuji-Garin S, Boudou-Rouquette P, et al.
J Clin Oncol
. 2025 Jan;
JCO2400117.
PMID: 39854651
Purpose: Establishing an accurate prognosis remains challenging in older patients with cancer because of the population's heterogeneity and the current predictive models' reduced ability to capture the complex interactions between...
3.
Joly F, Bazan F, Garbay Decoopman D, Garbay D, Ouldbey Y, Follana P, et al.
JNCI Cancer Spectr
. 2024 Dec;
9(1).
PMID: 39673810
Background: Maintenance niraparib at an individualized starting dose (ISD) is established in platinum-sensitive recurrent ovarian cancer (PSROC). However, patients' perspectives on the burden of prolonged maintenance therapy have not been...
4.
Guegan J, Peyraud F, Dadone-Montaudie B, Teyssonneau D, Palmieri L, Clot E, et al.
Cell Rep Med
. 2024 Nov;
5(12):101831.
PMID: 39591972
Immune checkpoint inhibitors (ICIs) have advanced the treatment of non-small cell lung cancer (NSCLC). This study evaluates the predictive value of CD8 T cell exhaustion in patients with lung adenocarcinoma...
5.
Franzoi M, Ferreira A, Lemaire A, Rodriguez J, Grosjean J, Ribeiro J, et al.
Lancet Reg Health Eur
. 2024 Oct;
44:101005.
PMID: 39444707
Background: Remote patient monitoring (RPM) of symptoms using electronic patient reported outcomes (ePROs) has been shown to reduce symptom burden and hospitalizations, increase dose intensity and improve quality of life...
6.
Paillaud E, Galvin A, Doublet S, Poisson J, Gay P, Perrin C, et al.
Patient Educ Couns
. 2024 Sep;
130:108420.
PMID: 39303502
Objectives: To evaluate health literacy (HL), assess the use of digital tools/sources, and identify factors associated with low or moderate HL in older (aged ≥65) and younger (18-64) patients with...
7.
Kabirian R, Tredan O, Marme F, Paoletti X, Eberst L, Lebreton C, et al.
Future Oncol
. 2024 Aug;
20(35):2699-2708.
PMID: 39155847
Ovarian cancer is a leading cause of death from gynecological cancers worldwide. Platinum-based chemotherapy provides the cornerstone of the medical management. In first line and subsequent relapses, maintenance strategies are...
8.
Rhanine Y, Bonnefoi H, Goncalves A, Debled M, Moulec S, Bonichon N, et al.
Breast
. 2023 Dec;
73:103667.
PMID: 38160476
Antiandrogens (AA) have been tested in clinical trials in androgen receptor (AR) + triple-negative breast cancer (TNBC). We aim to assess the clinical benefit rate (CBR) of AA in real...
9.
10.
Grellety T, Hajjaji N, Petit T, Bailleux C
Bull Cancer
. 2022 Oct;
110(1):69-87.
PMID: 36307325
HR+ breast cancers are defined by the prominence of signaling pathways dependent on the estrogen receptor. Endocrine therapy is the standard treatment for these advanced diseases. Resistance to these treatments,...